To optimize therapeutic outcomes in melanoma through targeted radionuclide therapy, a research team [15] developed 177Lu-labeled ultrasmall fluorescent core-shell silica nanoparticles and designed PEGylated Cornell prime dots (C′ dots) to target overexpressed MC1-R. The gene discussed is MC1R; the disease is melanoma.